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LONGITUDINAL CHARACTERIZATION OF DEPRESSION AND MOOD STATES
BEGINNING IN PRIMARY HIV INFECTION. Jessica A. Gold, Marie Grill, Julia
Peterson, Christopher Pilcher, Evelyn Lee, Frederick M. Hecht, Dietmar Fuchs,
Constantin T. Yiannoutsos, Richard W. Price, Kevin Robertson, and Serena Spudich.
Department of Neurology, Yale University, School of Medicine, New Haven, CT.
Though depression is known to frequently afflict those with chronic HIV, mood during
the early course of HIV is not well characterized. In a prospective study we assessed
mood during primary HIV infection (PHI, <1 year duration), its association with
neuropsychological performance and markers of neurological disease, and its longitudinal
course including effects of highly active antiretroviral therapy (HAART). The Beck
Depression Inventory (BDI) and Profile of Mood States (POMS) subscales were
longitudinally administered prior to and after HAART in PHI subjects. This evaluation of
mood was done concurrently with blood, cerebrospinal fluid (CSF) and
neuropsychological (total z and global deficit score, GDS) evaluation at each visit.
Analysis employed Spearman’s rho, logistic regression, and linear mixed models. 47.7%
of the 65 men recruited at a median 3.5 months HIV duration met BDI criteria for clinical
depression at baseline, classified as ‘mild’ (n=11), ‘moderate’ (n=11), or ‘severe’ (n=9).
Drug, alcohol, and depression history did not associate with BDI score. Proportional
somatic-performance scores were worse than cognitive-affective scores (p=. 0045). Vigor
subscore of POMS was reduced compared to norms and correlated with total z (r=0.33,
p=0.013) and GDS (r=-0.32, p=0.016). BDI and POMS correlated with one another
(r=0.85, p< .0001), but not with CSF or plasma HIV RNA, white blood cell (WBC)
count, albumin ratio or neopterin. Improvement was not observed in BDI and POMS over
330 total follow-up visits, even after initiation of HAART. Depression was prevalent

during PHI in our subjects, associated with abnormal somatic-performance and vigor
scores. Neither neuropsychological performance nor disease biomarkers correlated with
depressed mood. Mood indices did not improve over time in the presence of HAART.
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INTRODUCTION
HIV/AIDS: The Problem in the U.S.
“When I tested positive it was very clear to me that I would die”(1).
Knowing that this quotation comes from an interview with an HIV-infected person within
2 months of diagnosis, one might expect this person to have been diagnosed in the early
era of HIV infection, the 1980s. This assumption occurs because over the past few
decades, the picture of HIV/AIDS in the United States has changed dramatically.
Research advances have helped to: prevent vertical transmission (mother to child),
improve screening blood and blood products for the virus, and develop successful
treatment regimens (2). With suppressed viral replication due to highly active
antiretroviral therapy (HAART), patients are also less infective to their sexual partners
(3). As a result, there has been a significant decline in the HIV infection rate in the
United States from 130,000 new cases a year in 1984 to 60,000 in 1991 (2) (See Figure
1) (4).
Beyond the decrease in new cases, HIV is also no longer unavoidably fatal. In
fact, the loss of life years due to HIV (approximately 7) is equated to that due to a
lifetime of cigarette smoking, or close to the levels of the uninfected population with
chronic disease (5,6). Additionally, AIDS-related illnesses, such as pneumocystis
pneumonia, are no longer the primary causes of death in AIDS patients, and instead, new
complications of chronic disease have taken their place (7). In just a few decades, HIV
has gone from a fear-inducing disease that was a death sentence, to a chronic illness that
is manageable with medication (8). In response, much of our public health focus and
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attention has turned to Sub-Saharan Africa where 2/3 of the cases of AIDS now reside
(2).

Figure 1. AIDS in the US from 1981 to 2008: Diagnoses, Deaths, and Living with
HIV Infection or AIDS in Persons 13 or Older. Following the introduction of HAART
around 1995, there has been a stable incidence of approximately 50,000 new cases/year.
Source: CDC. Morbidity and Mortality Weekly Report. HIV Survelliance-US, 1981-2008.
2011; 60(21):689-693.
However, the initial expectation that the patient interviewed above was
interviewed in the 1980s, is wrong. In fact, this study was conducted within the past year.
While there have been vast scientific advances, a decrease in incidence and mortality, and
a change to the cultural concept of HIV as a disease, fear about HIV persists. Why is it,
then, that this patient, and 23% of the rest of the interviewed sample, still feel that HIV is
a fatal diagnosis (1) ?
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Perhaps this is because that while the incidence of HIV has remained stable at
about 50,000 new cases of HIV a year in the US (9) (Figure 1), certain high risk groups,
such as the 86% men who have sex with men (MSM) interviewed for the study (1), are
disproportionately affected (See Figure 2)(10). In some urban areas, the HIV prevalence
among MSM is as high as 30%, a number significantly greater than the general
population prevalence of both Kenya (7.8%) and South Africa (16.9%)(2). Clearly, the
burden of HIV infection today is not solely an international problem.

Figure 2: Rates of New HIV Infections in the US in 2010, by High-Risk Subgroup.
HIV in the US disproportionally affects African Americans and Hispanics as well as
MSM. Source: CDC.HIV in the US: At a Glance.http://www.cdc.gov/hiv/statistics/basics/
ataglance.html
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Beyond greater concentrations of disease in disadvantaged populations and a
greater concentration of HIV in urban areas, with 50% of persons living with HIV in the
US located in only 12 cities (9) (see Figure 3), new cases are also found much more
commonly in these groups. In fact, even though MSM represent about 4% of the male
population in the US, they account for 63% of all new infections (10). This percentage,
unlike the overall incidence of HIV in the US, has not remained stable. Instead, it has
increased 12% in just two years (from 2008 to 2010) (10). In addition to MSM, HIV in
the US also disproportionally affects African Americans and Hispanics. While African
Americans represent only 12% of the US population, they account for more than 44% of
the new HIV infections (10,11). Hispanic males are also disproportionally affected,
infected at 2.9 times the rate of new infections in white males (10). Other risk factors
such as intravenous drug use (IVDU), excessive alcohol and cocaine intake, and risky
sexual behaviors continue to pose a threat for HIV acquisition (2), and as a result, HIV is
found more often in populations with more risk. In these social and sexual networks, HIV
remains highly concerning and even subjectively instills a sense of impending doom
around the diagnosis.
Additionally troubling, despite widespread screening methods, is the fact that 1 in
6 persons living with the disease are unaware of their status (11). This means that despite
effective treatment, patients will present late in the course of their infection, decreasing
their life expectancy and increasing the probability of transmission to others (6). Stigma
remains a serious impediment to screening and ultimately treatment (1). Given these
discrepancies, it is clear that combating HIV/AIDS in the US is not finished and remains
a significant public health issue, especially in populations that are “disenfranchised and
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socially marginalized” (2). It is thus understandable that the patient interviewed felt HIV
was still a death sentence in 2013.

Figure 3: A Map of the Diagnoses of HIV Infection in 2010.
In 2010, the estimated number of new diagnoses of HIV infection in the US was 48,298.
This rate varies widely across the US and US dependent areas: from zero in American
Samoa and the Northern Mariana Islands to 6,417 in California. Source: CDC. HIV
Surveillance Report , 2011; vol. 23. http://www.cdc.gov/hiv/topics/surveillance/
resources/reports/. Published February 2013.
HIV/AIDS: The Disease and Its Treatment
Acknowledging the problem of HIV in the US, it is also important to understand the
basics of the virus’s time course and treatment. HIV is a retrovirus (more specifically a
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lentivirus) that can be transmitted from sexual contact, IVDU, contact with infected blood
products, or from mother to child (12). It infects cells in the immune system, such as
helper T cells, macrophages, and dendritic cells, following the interaction of a viral
surface protein known as the glycoprotein 120 (gp120) and CD (or the cluster of
differentiation) receptor number 4 (CD4), which is expressed on T-lymphocytes,
monocytes, macrophages, and dendritic cells (13). Once the virus enters the cell and HIV
RNA is reverse transcribed to DNA, the virus can either lie dormant in the latent phase of
infection or lead to a decline in CD4 (through mechanisms such as apoptosis and killing
of infected cells (14)). This decline will ultimately cause a decrease in cell-mediated
immunity, or, more specifically, will decrease the body’s ability to fight infection (12).
The clinical presentation of HIV begins with primary HIV infection (PHI), in
which a patient develops a “flu-like” syndrome approximately 14 days following
transmission (see Figure 4). Clinically, patients may experience a fever, fatigue, sore
throat, a rash, and even a headache, while biologically there is an increase in HIV RNA
and a decrease in CD4 count (15,16). During this period, health care providers often miss
the diagnosis of HIV, and, in one study only 25% of patients were correctly diagnosed by
providers during an appointment in this time period (15). This early period, however, is a
critical time for the course of infection as HIV tissue reservoirs and CD4 memory
phenotype T-cells are produced, and viral and immune activation set points are
determined (17). Virus can also be found in immunologically privileged areas in the
CNS, such as the brain and spinal fluid, during this time (18,19)
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Figure 4: Typical Course of HIV Infection in an Untreated Individual. In this figure,
red represents CD4 count and blue the HIV RNA copies/ml plasma. Notice how primary
infection is associated with a rise in the plasma HIV RNA within the first three weeks of
viral infection. Patients then develop anti-HIV cytotoxic T lymphocytes causing the CD4
count to decline. After a brief recovery of immune cells, infected individuals enter
clinical latency, in which the CD4 count declines slowly over time. If HAART is not
initiated, the CD4 count falls to a critically low level, the patient is susceptible to
opportunistic infections, and will develop AIDS. Re-Printed with permission courtesy of
A.S. Fauci, National Institute of Allergy and Infectious Diseases, NIH
	
  
Following primary infection, the massive peak in the plasma viral load subsides as do the
clinical symptoms and the patient reaches the clinically quiescent phase. In this phase,
viral particles are produced at a high rate, and CD4 cells are destroyed and replenished
daily (20, 21). Over time, a patient’s CD4 cell count will decrease substantially and
individuals will become susceptible to severe infections and the development of AIDS.
This time span ranges from less than one year to more than 20 (21).
In terms of treatment, the first antiretroviral drug was introduced in 1987,
zidovudine, and for many years this drug, and others in the nucleoside reverse
transcriptase inhibitors class were used as mono, and the only available, treatment.
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Approximately 10 years later, protease inhibitors and non-nucleoside reverse
transcriptase inhibitors were introduced. The discovery of these additional classes of
drugs subsequently led to combination therapy, or the use of three drugs, from 2 different
classes. This treatment modification, now known as HAART, extended survival
dramatically (12). Yet, because of the blood-brain-barrier (BBB), HIV in the brain can be
protected from the full effect of antiretroviral agents, especially those drugs that are large
or hydrophilic. To date, studies have found choosing drugs with higher CNS-penetrationeffectiveness scores (CPE) can lead to more effective viral suppression (22,23), however,
this is not yet recommended practice.
Over the years, treatment guidelines for clinicians have changed with the most
current recommendations suggesting that HAART be offered to all patients regardless of
their CD4 count (24). However, a patient’s willingness to take the treatment consistently,
challenged, in part, because of significant drug side effect profiles including
lipodystrophy, lactic acidosis, and insulin resistance, is a significant factor in treatment
success (12). Drug resistance can occur in the setting of poor adherence secondary to the
high replication rate of HIV infection and the high error rate of reverse transcriptase (12).
Clinically, patients will observe a decreased susceptibility to a specific drug, and
ultimately, may fail to have a beneficial response to their HIV treatment regimen.
At first thought to potentially cure HIV, it is now recognized that HAART is not a
cure, but is instead a life-extender. This is because HIV also infects long living cells like
microglia and has latency in memory CD4 cells (25), and therefore, never entirely goes
away. Though the CD4 count in treated patients will often increase (improve) over time
suggesting a greater ability for the patient to fight infection, immune dysfunction,
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inflammation, and coagulation disorders will persist. HIV-infected patients are then at
high risk for cardiovascular, kidney, and liver disease, as well as malignancy (7).
Additionally, it is believed that HIV can affect the central nervous system (CNS), in part,
because HAART is systemically suppressive, allowing infection, inflammation, and brain
injury to remain active and progressive over time (17).
HIV/AIDS in the Central Nervous System: Mechanism and Effects
Though reasons that HIV is able to impact the nervous system during HAART remain
hypothetical, what is known is that HIV entry is associated with immune activation and
inflammation in the CNS. The virus is able to traverse the BBB in infected monocytes
and lymphocytes, (26) (See Figure 5, a), a hidden mechanism often referred to as the
“Trojan horse.” Once inside, the monocytes change into perivascular macrophages and
eventually release viral proteins that are known to exert toxic effects upon neurons or
astrocytes (17). Microglia also become infected (27)(See Figure 5,b) and in some cases
form large multinucleated giant cells with infected macrophages that serve as a virus
production reservoir (see Figure 5,c). Infected cells further promote astrocytosis with the
dysregulation of cytokine production. These cytokines inappropriately act to recruit
activated T-cells from the periphery and activate uninfected cells. Ultimately, this will
lead to a further increase in the permeability of the BBB and additional leakage of cells
and inflammation products into the CNS (12,27).

10

Figure 5: HIV Invasion of the CNS. HIV uses a Trojan horse mechanism to enter the
BBB in infected monocytes. Inside, these become perivascular macrophages and
microglia. Infected cells will induce astrocytosis and further increase permeability of the
BBB. Reprinted by permission from Macmillan Publishers Ltd:[Nature](GonzálezScarano, F.& Martín-García, J. (2005). The neuropathogenesis of AIDS. Nature Reviews
Immunology, 5(1), 69-81), Copyright (2005), as well as Drs. González-Scarano and Julio
Martín-García
The CNS is infected very early in the course of HIV infection, during primary
HIV (15). Even in the early months of infection, HIV is associated with inflammatory Tcells in the brain, an increase in cytokines, and the activation of microglia (17). The CNS
reservoir for infection and inflammation is also established during this time period (17).
Following the clinical picture of an acute retroviral syndrome, some infected individuals
will develop neurological complaints, such as meningitis or encephalitis. As these
symptoms are often self-limited, they are believed to be autoimmune in etiology (17).
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Yet, the persistence of HIV associated cognitive impairment, despite the initiation and
success of HAART, suggests that this early period, before even the HIV diagnosis is
made, might cause irreversible damage to the CNS in infected persons (17).
In the days before HAART, one of the more common manifestations of HIV
infection, occurring in up to 70% of infected individuals, was neurological disorders (28).
More often associated with advanced illness and not primary infection (29,30), these
disorders included opportunistic infections such as toxoplasmosis, progressive multifocal
leucoencephalopathy (PML) and primary CNS lymphoma, as well as the previouslynamed AIDS dementia complex (31). In the latter, now called HIV-associated dementia,
patients presented with cognitive, motor and behavioral symptoms, but would often only
receive this diagnosis when all other causes were ruled out (32). At first these patients
would have difficulty concentrating and have mental slowing, and over time, developed
motor symptoms including slowing of rapid movements and hyperreflexia (33).
Additionally, one large study found that in 1/3 of patients behavior change including
apathy and social withdrawal was prominent (32).
With the discovery of HAART, HIV-Associated Neurocognitive Disorder
(HAND) no longer manifests as HIV-associated dementia, but is instead presents as more
subtle disturbances in psychomotor speed, processing speed, executive function, and/or
memory (17). The disorders may be milder than in the pre-ART era, but the presence of
cognitive impairment is still associated with an increased overall disease morbidity,
thought due in part to low adherence to medication regimens in these patients (34).
Additionally, HAND has been shown to correlate with the CD4 nadir (34), suggesting
that patients with the largest immunologic ‘hit’ from HIV are most prone to develop
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neurocognitive dysfunction. Ultimately, even in the presence of successful treatment with
HAART, patients continue to be affected by HAND today.
HIV and Depression
Patients with chronic medical illnesses have, in general, a two-to-threefold higher rate of
major depression compared with age and gender matched patients who do not have a
chronic illness (35). This is particularly significant as depressed patients appear to die 5
to 10 years earlier than patients without psychiatric disorders (35). In addition, the
patients who are also depressed more often report higher numbers of physical symptoms
such as fatigue (even when controlling for severity of the baseline medical disorder)
(35,36), have higher levels of subjective pain assessment, and contribute to a two-fold
higher cost to the medical system (36). This cost is often secondary to increased
functional impairment, twice as many health care visits, and a three times lower
adherence to self-care regimens in this population (35). Yet, improving depression
decreases somatic symptom complaints in these patients (36) and improves health care
outcomes. That being said, given that HIV in the post-ART era has been transformed to a
chronic illness (7), depression in this population can be presumed to be costly, both to the
patient and to the health care system.
Reports of the prevalence of depression over the course of HIV infection vary
widely (37-39), however, one meta-analysis found that the diagnosis of Major Depressive
Disorder is nearly twice as likely in HIV-infected persons as compared to those without
HIV (39). Major Depressive Disorder can be defined using the DSM IV classification, in
which a patient must have depressed mood and/or loss of interest or pleasure in life
activities plus 5 of the following symptoms for at least 2 weeks: depressed mood, loss of
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interest, significant unintentional weight gain, insomnia, psychomotor retardation, fatigue
or less of energy, feelings of worthlessness or guilt, diminished concentration, and
suicidality (40). One reason for such a strong association between depression and HIV
may be overlap in symptoms between depression and HIV infection itself, as appetite
disturbance, fatigue, and concentration problems are all associated with HIV as well as
depression (38,41-43). In fact, frequency of HIV symptoms and symptom distress were
found to increase with level of depression or anxiety (44). Yet, studies suggest that
depression is symptomatically different between HIV-infected and HIV-uninfected
persons. The most common symptoms reported among HIV-infected subjects is sleep and
appetite disturbances, while HIV-uninfected subjects more commonly endorse decreased
energy and libido (38). Additionally, depressive symptoms can be caused by both the
opportunistic infections associated with HIV, which alter mood and cognition, and the
side effects of antiretroviral therapy, which can cause agitation, depressed mood,
decreased cognition and insomnia (38). One study found that more side effects from
treatment predicted depression (45). Complicating matters further, variables such as
employment status, gender, history of attempted suicide, sexual orientation, history of
depression, illicit drug use, drug dependence, heavy alcohol use (more than 7 drinks a
week for a woman and more than 14 for a man), and social class are all independently
associated with increased risks of depression and can subsequently alter the prevalence of
and susceptibility to of depression in this population (37,38,46-48). Stigma in this
population, which leads to isolation and lack of social support, is also correlated
significantly with higher levels of depression (45,48,49). Perhaps because physicians
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attribute behavioral change to the disease itself, depression in HIV infected persons often
is underdiagnosed (38).
Though it is known that depression is common in HIV infection, it is not clear
when depression arises during the course of infection or how this relates to other events
of HIV pathogenesis. In general, cross-sectional rates of Major Depressive Disorder are
similar in asymptomatic disease and in more advanced HIV disease (39). Unlike in the
general population, depression rates do not seem to decline with age in HIV infected
populations (47). Indeed, studies have shown no increase in the rates of depression in
later stage disease even in patients more medically ill (43,50), and have found no
consistent association with either CD4 cell count or HIV viral load (39,51,52). For
example, some studies have found an association between low CD4 count and
depression, while others found no association. Depression has also not conclusively been
found to affect performance on neuropsychological testing (37,53,54). Despite an
unclear association between depression and these medical and neurological aspects of
HIV infection, one study did find that depressive symptoms were associated with an
increased mortality in HIV-positive women (43,55).
It is often debated whether, when depressed mood and HIV infection are
identified concomitantly, depression was a premorbid condition in a person who was at
high risk of HIV acquisition, or whether depression followed HIV infection. There are
theories, however, suggesting that there may be a biological basis to the depression seen
in HIV infection. One idea is that the cytokines produced by the macrophages in the HIV
infected CNS lead to depression (48,56). This concept is supported by the discovery of
elevated inflammatory markers, such as cytokines, in depressed human patients, the
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finding of high levels of depression in people with inflammatory illnesses, and the
relation between acute inflammation in mammals and behavioral changes similar to
depression known as “sickness behavior” (56). Another hypothesis suggests that gp120
inhibits the dopamine transporter, increasing dopamine levels in the synapse and
promoting HIV replication. HIV then destroys the dopaminergic basal ganglia neurons
leading to depression (48,56). A final theory suggests that stress from illness increases
corticotropin releasing hormone and cortisol levels, leading to depression (38,48,56). On
the other hand, some argue that mood changes in this population could have preceded
infection with HIV, instead of secondary to the illness itself (57). This means that those
with a history of a mood disorder, or those populations at high risk of having a mood
disorder (MSM and IVDU), are at an increased risk for contracting HIV (58). Whether
behavioral, social, or reactionary, this risk for HIV infection in populations with a high
baseline risk of depression leads to higher rates of depression overall in this population
(43). Developing depression may then either be a result of previous depression, or HIV’s
affects on the CNS (59).
While the timing of the relationship between initiation of depression and HIV
remains unproven, what is evident is that depression can impact HIV disease progression
and treatment outcomes. Having depression is associated with a faster progression to
AIDS and increased risk of mortality associated with HIV (59). While this may be related
to an association between depression and impaired immune function (53), it may also
correlate with decreased medication adherence and incomplete virologic suppression (38,
43, 52) among HIV infected individuals on HAART. In fact, in one meta-analysis,
depression was consistently associated with non-adherence in all samples over time (60).
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This effect (r-.19) was similar to the effect (r=.21) in meta-analyses of depression and
other chronic illnesses (60). Additionally, as one study found an inverse association
between depression and HAART, suggesting lower levels of depression in patients on
HAART, and this association was found to increase with time on HAART, some
postulate there is a protective effect of HAART on patients against depression (61).
Given that non-adherence is associated with an increase risk of treatment failure and viral
resistance, and, that there are potential mood benefits to using ART, diagnosing and
properly treating depression in HIV infected patients becomes critical.
In this population, study after study has suggested the benefits of antidepressant
use. Antidepressants have been shown to be an effective treatment for HIV infected
patients with depression (38,41,58,62); antidepressant use in one month has been
associated with a 28% increase in the odds of HAART use in the subsequent month (63).
Furthermore, in a different study, the odds of adhering to HIV-treatment were 83% better
if a patient was having their depression treated (64). In terms of which antidepressant is
safe and effective in this population, though serotonin reuptake inhibitors (SSRIs) were
found to be as effective as tricyclics, SSRIs were often the drug of choice due to their
much safer side effect profile (38,43). Nonetheless, as remission of depression was
associated with lower viral load or a decrease in the amount of virus (65), treating
depression is crucial for medication adherence, and treating HIV.
For all of these reasons, understanding and treating depression in HIV-infected
patients is of central importance in improving clinical outcomes. With new HIV clinical
practice guidelines (24) recommending treating all HIV-infected patients with HAART,
including those in very early HIV infection, early interventions to enhance adherence to
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HAART and its effectiveness will be critical in preventing the transmission of drug
resistance. Better understanding of the role of depression in the early stages of HIV has
emerged as an important question in the public health approach to HIV treatment.
This study seeks to elaborate on our understanding of HIV and depression by
focusing on subjects with primary HIV infection (PHI), or those infected within the past
year. As mentioned previously and clarified here, during the early weeks after exposure
to HIV, up to 10% of individuals develop neurological signs and symptoms of disease,
and HIV can be detected in both cerebrospinal fluid (CSF) and brain tissue (18,19). PHI
is also associated with impaired performance on neuropsychological testing and with
neuroinflammation as measured in CSF (66,67). Yet, to date, only one study has looked
at and reported on the prevalence of symptoms and signs of mood disorders during the
early stages of HIV infection (68). This study measured depression in 34 individuals with
PHI using qualitative methods (the Mini International Neuropsychiatric Interview) and
quantitative self-report comparisons (the Beck Depression Inventory (BDI), the StateTrait Anxiety Inventory). The authors found that almost 40% of their subjects were
categorized as depressed in the clinical range, though most depression was “mild”, and
that subjects had a strong reliance on adaptive coping approaches (68). We aimed to
further characterize depression in PHI, by assessing mood states in subjects with PHI
with additional measures, and correlating mood indices with measures of CNS
inflammation and infection in the CSF and with measures of cognitive performance. In
addition, we longitudinally assessed mood scores in this observational study, including
visits both prior to and after initiation of HAART, to evaluate the trajectory of depression
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in this population over time and association of mood scores with the commencement of
HAART.

HYPOTHESES
Depression and otherwise altered mood states are prevalent in the first months after HIV1 transmission (during PHI) and will persist longitudinally despite initiation of HAART.
Indices of altered mood states may correlate with CNS inflammation as measured in CSF,
or with performance on neuropsychological testing.

SPECIFIC AIMS
1) To quantify and describe the extent of depression symptomatology and the range of
mood states of individuals during the first six months after HIV exposure based on
baseline scores on the validated Beck Depression Inventory (BDI) and Profile of Mood
States (POMS) assessments obtained from a cohort of subjects with primary HIV
infection.
2) To investigate whether baseline levels of depression in PHI (as measured by the BDI
and POMS) correlates with known biomarkers of HIV burden and inflammation and host
responses in the CNS to infection.
3) To examine whether the baseline levels of depression in PHI (as measured by the BDI
and POMS) correlate with cognitive impairment based on neuropsychological testing.
4) To longitudinally assess mood states in patients with HIV, from acute infection to up
to 3 years post infection, taking into account the effects of HAART initiation in this
cohort.
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METHODS
As lead investigator on this highly collaborative project, Jessica Gold was responsible for
the key aspects of the study. Importantly, she conceived of the study concept. Though
the cohort study was planned and implemented prior to her participation and relevant data
to this project was in the process of collection, the specific analysis of mood features in
correlation with laboratory and clinical features was an idea that she developed and
pursued. After planning the study design and analysis, plan, she performed all of the key
aspects of implementing the project, including reviewing the subject data and excluding
inappropriate subjects, cleaning the dataset, tallying the mood inventory data from
individual forms filled out by study subjects, organizing the data into spreadsheets, and
performing data analysis. She performed all of the baseline cross sectional analysis and
summary statistics, and worked closely with Dr. Constantin Yiannoustsos, a professor of
statistics, to perform the complex analysis of longitudinal data. She also was responsible
for creating figures and tables, as well as all of the writing that accompanied the research,
with editing help from Dr. Serena Spudich and other collaborators. The other
investigators were responsible for recruiting subjects, collecting or storing specimens,
neuropsychiatric testing, conducting detailed medical histories, and performing
laboratory assays. Collaborators also worked closely with the primary author in
performing the complex statistics required for cofounders analysis (such as substance
abuse) and the complex longitudinal data analysis and graphing as noted above, as well
as assisted with normalizing the neuropsychiatric data.
Study Design and Subjects
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Study subjects were enrolled in an observational longitudinal neurological study of PHI
based at the University of California, San Francisco (UCSF), the Primary Infection CNS
Events Study (PISCES)(66). Subjects with known or suspected HIV infection within the
past year were referred to PISCES from local HIV testing centers or from a parallel
systemic study of PHI, the UCSF Options Study. Subjects were over the age of 18,
identified within the first twelve months after HIV-1 transmission as defined either by
seroconversion on standard HIV serologic testing or by a less-sensitive HIV antibody
EIA indicating early infection as previously described for this cohort (69,70). For
subjects reporting classic acute retroviral symptoms within the seroconversion period,
infection was estimated as having occurred 14 days prior to onset of acute retroviral
symptoms (71). In the absence of such symptoms, the infection date was estimated as
occurring halfway between the last negative and first positive HIV test (72).
Study visits occurred at baseline, 6 weeks, 6 months, and every 6 months
thereafter indefinitely. Subjects were HAART naïve at the first visit, and some started
HAART at variable times during the course of follow-up for reasons outside of the
observational study. At each visit, subjects underwent a record review, a full neurological
history and examination, a detailed battery of neuropsychological testing, depression
screening, and lumbar puncture and phlebotomy. The Institutional Review Boards at
UCSF and Yale approved study protocols, and informed consent was obtained from all
subjects.
Depression Measures
The BDI-II (73) and POMS (74) measures were administered at each study visit. Study
subjects completed these instruments using the standard instructions and with the help of
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study staff that were available for questions and to make sure that subjects understood
and properly completed the screens.
The BDI-II consists of 21 items. Study subjects choose a phrase that is most
associated with how they are feeling ranked on a Likert Scale. The total number of points
for the entire instrument is then calculated to measure the total BDI score; higher scores
indicate a more severe depression. The standard cut-offs for the BDI-II indicate that a
score of 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate
depression, and 29-63 is severe depression. In addition, to properly compare with the
study by Atkinson et al, the only other study of depression in subjects with PHI, clinical
depression was defined as a total BDI>13 (68). To calculate BDI subscale scores, items
1-13 scores were tabulated for the cognitive/affective score, which includes items such
as self-dislike, pessimism, and worthlessness, and the points for the remaining items (1421) were summed for the somatic score, which involves such symptoms as change in
appetite, loss of interest in sex, irritability, and concentration difficulties (75). Proportions
were calculated to compare the subscale scores to each other by dividing the raw score by
the possible total score for each subscale.
The POMS consists of 65-words or brief phrases on a Likert scale. Raw scores for
the mood states of depression, tension, anger, fatigue, confusion, and vigor are then
calculated using standard analysis methods leading to a raw score of <60 for each mood
state. Total Mood Disturbance (TMD), is calculated by the sum of the raw scores from
tension, depression, anger, fatigue, and confusion, with the vigor score subtracted. This
gives a TMD in the range of -24 to 177, with a lower score representing more stable
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mood. In our analysis, subscale and total scores were converted to z scores for
normalization.
Specimen Sampling, Processing and Laboratory Studies
CSF, blood, and general medical and neurological assessments were obtained as
previously described (76,77). Briefly, this involved CSF collection via lumbar puncture,
wherein subjects, after specific consent for lumbar puncture procedure, were prepped and
draped, lay in a lateral supine position, and had a small amount of 1% lidocaine
introduced subcutaneously and then in the slightly deeper soft tissues for local anesthesia.
After accomplishment of anesthesia, a Sprotte pencil point CSF collection needle with
introducer was inserted into the anesthetized space and approximately 20 cc of CSF was
collected. After the procedure, subjects rested and underwent phlebotomy for blood
collection for paired blood lab analysis. From CSF, total white blood cell (WBC) count,
protein, and albumin were measured in the clinical laboratory on fresh samples. From
blood, background labs including complete blood count and chemistries, as well as blood
albumin and blood CD4+ and CD8+ T lymphocyte counts by flow cytometry were
measured on fresh samples. The remainder of the samples were centrifuged and cell-free
CSF and blood plasma were also aliquoted and stored within 6 hours of collection in -70
deg C freezers monitored for temperature on a daily basis using NIST-certified
thermometers.

Immune Biomarker Methods
CSF and plasma concentrations of the macrophage activation marker neopterin
(BRAHMS Aktiengesellschaft, Hennigsdorf, Germany) was measured in previously
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frozen samples in the laboratory of Dr. Fuchs by commercial immunoassay. Neopterin is
a sensitive measure for cellular immunoactivation (78) and chemokines mediate HIVinfected leukocytes through the BBB. MCP-1 recruits monocytes and macrophages,
typically at low levels in asymptomatic HIV-infected individuals (79 80).
CSF chemokines interferon-inducible protein-1 (IP-10) and monocyte-chemoattractant
protein-1 (MCP-1, R&D Systems, Minneapolis, MN) were also measured in previously
frozen samples locally at UCSF by commercial immunoassays. IP-10 is produced by Tcells, macrophages, astrocytes, and endothelial cells, and attracts immune cells, primarily
T lymphocytes, from the periphery across the blood brain barrier (81). Levels of IP-10
often correlate with CSF mononuclear and HIV RNA levels (82). MCP-1 is also
produced by immune cells including resident microglial cells and macrophages within the
CNS, primarily attracts monocytes across the blood brain barrier, and in advanced HIV is
highly correlated with presence of HIV dementia.

Virological Methods
HIV RNA levels were measured in previously frozen cell-free CSF and plasma using the
ultrasensitive (50 copies/mL lower limit of detection) Amplicor HIV Monitor (version
1.5; Roche Molecular Diagnostic Systems, Branchburg, NJ), or the Abbott RealTime
HIV-1 (Abbot Laboratories, Abbot Park, IL, USA) assays. Paired blood and CSF
measurements were made using the same assay, typically in the same PCR run.
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Neuropsychological Testing
Neuropsychological testing performed by a trained psychometrist employed an 11 test
battery encompassing five neurological/cognitive domains, including motor (timed gait,
grooved pegboard, finger tapping, non-dominant hand); executive function (trailmaking
B & Controlled Oral Word Association Test); processing speed (WAIS-R digit symbol,
trailmaking A); memory (RAVLT delay, figure delay); and learning (average of RAVLT
trials 1-5, figure memory learning). All measures except timed gait were normed
according to age, education, gender, and ethnicity. Measures were summarized as a brief
NPZ4 (average of performance on 4 tests: timed gait, grooved pegboard, finger tap and
digit symbol), total Z (average of performance on all 11 tests), and global deficit score
(uses a standardized conversion table to convert demographically corrected Z scores on
individual NP measures to deficit scores ranging from 0 (no impairment) to 5 (severe
impairment)).

Statistical Analysis
Baseline descriptive statistics were performed using GraphPad Prism (version 5.0,
GraphPad Software, San Diego, USA). Spearman’s non-parametric correlation was used
for correlation between measured parameters at baseline. Cross-sectional baseline group
differences were detected through the Mann-Whitney rank sum test and the KruskalWallis test with post-hoc testing corrected for multiple comparisons. Longitudinal
analysis was performed using SAS (version 9.0, SAS Institute, Inc., Cary, NC) and
employed a mixed-effects model with covariates of weeks of infection and time-by-ART
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interaction in subjects starting HAART to analyze longitudinal BDI and POMS total
scores.

RESULTS
Baseline Study Subject Characteristics
65 subjects (all men) with a median age of 36 qualified to participate in this study. They
also had a median of approximately 3.5 months (103.5 days) of infection at baseline, and
median CD4 count of 558. One subject included in this study who met BDI criteria for
severe depression committed suicide after the first visit. Other baseline features of the 65
subjects (including prior treatment for depression and substance use) are presented in
Table 1.
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Table 1: Baseline Characteristics of Study Participants. N = 65 subjects, 100% male,
all but 3 self-identified as MSM
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Baseline Analysis of BDI and POMS Scores
According to BDI definitions (total score >13), 31 (48%) of the 65 subjects met the
criteria for clinical depression at baseline. Of those subjects, 11 had ‘mild’ depression, 11
had ‘moderate’, and 9 had ‘severe’ depression (See Figure 6). A comparison of somatic
performance proportional scores to cognitive-affective performance proportional scores,
showed somatic scores were worse than cognitive-affective scores (medians 0.29 vs 0.15,
p=.0045) (See Figure 7).

	
  
Figure 6: Depression During PHI by BDI Definition. Baseline depression severity in
PHI subjects based on total BDI scores. 47.7 % met BDI criteria (total score > 13) for
clinical depression.
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Figure 7: Baseline BDI Subscale Scores. BDI subscale scores presented as a proportion
of total possible points per scale. Subjects reported greater somatic than affective
symptoms. Bold lines denote median value.
Per the POMS measurement, the median Total Mood Disturbance was 44 (range 21 to 167, with standard deviation of 41.64). Figure 8 shows the comparison between the
different POMS subscales according to Z score. Vigor was the only state reduced in PHI
subjects as compared to norms. The levels of tension, depression, confusion, anger and
fatigue were similar. Additionally, the BDI total score and POMS Total Mood
Disturbance score correlated with one another (r = .85, p<.0001) (see Figure 9). This
suggests internal reliability between the measures in our subjects, despite self-report.
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Figure 8: Baseline Mood States: POMS Subscale Scores. POMS subscale scores at
baseline. Only vigor was different (reduced) in PHI subjects compared with norms (Z
scores). Bars indicate median and interquartile range.
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Figure 9: Correlation Between POMS Total Mood Disturbance and BDI Total
Scores. Strong and significant correlation suggests internal consistency of these
measures in our subject cohort.
We sought to investigate the possible effect of variables that may be associated
with depression independent of HIV infection status on the mood states in our subjects.
Scores on the BDI did not differ between groups defined based on the subject’s history of
past drug use (p = 0.845), recent drug use (p = 0.885), alcohol abuse (p = 0.592), or prior
psychiatric history/treatment, including depression or bipolar disorder (p = 0.875).

Correlation of BDI and POMS Scores with Laboratory and Neuropsychological
Performance Indicators
No association was found between scores on BDI or POMS measurements and laboratory
measures of HIV infection or CSF markers (not shown in table) associated with blood
brain barrier breakdown (CSF: serum albumin ratio), macrophage activation (neopterin)
or chemoattraction of inflammatory cells into the CNS (IP-10 and MCP-1) (Table 2).

30
Similarly, scores on mood measures did not correlate with either brief or total
summarized NP measures, except an association between self-reported ‘vigor’ and better
performance. The vigor Z score (median=-0.6) was reduced and modestly
correlated with total z (r=0.33, p=0.013) and GDS (r= -0.32, p=0.016).

Plasma HIV
Total Global
CD4 count
RNA
CSF HIV RNA CSF NPZZ
Deficit
(cells/mm3) (log10copies/ml) (log10copies/ml) WBC
4
Score Score
r=
r= r= r=
r= -0.11
r= 0.03
r= -0.091
BDI Total
0.053 0.13 0.16
0.14
Score
p=
p=
p=
p=
p= 0.35
p= 0.80
p= 0.53
0.69
0.37 0.24
0.32
r=
r= r= r=
POMS
r= -0.13
r= -0.007
r= -0.032
0.077 0.055 0.17
0.18
Total Mood
p=
p=
p=
p=
Disturbance
p= 0.32
p= 0.96
p= 0.83
0.57
0.69 0.22
0.20
r= r=
r=
r= POMS
r= 0.55
r= -0.20
r= -0.071
0.13
0.18 0.33
0.32
Vigor
p=
p=
p=
p=
Subscore
p= 0.66
p= 0.10
p= 0.59
0.32
0.18 0.013 0.016
Table 2. Correlation Between Baseline BDI and POMS Scores and Laboratory
Parameters and Neuropsychological (NP) Performance. Spearman r correlation value
and p values are shown. Significant correlations are shown in bold. No significant
correlations were identified between POMS Tension, Anger, Confusion or Fatigue
subscores and lab or NP performance results.

Longitudinal Analysis of BDI and POMS Scores
Utilizing the same population of 65 subjects, we performed a longitudinal mixed-methods
analysis on POMS and BDI scores. Only 60 of the 65 subjects from the baseline analysis
could be used because 5 subjects did not have longitudinal follow-up. Understanding that
a higher score is consistent with more depression on both the POMS and BDI measures,
we did not detect a statistically significant improvement in the overall BDI either prior to
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or following HAART initiation (slope of change prior to treatment over time -0.02038
change per week, p=0.1238; slope of change following ART= -0.0020, p=0.9107). The
aggregate overall BDI trajectory (including pre- and post- HAART visits) also did not
significantly change over the course of follow-up (slope= -.02239, p=0.0748). On the
POMS, there was a small significant improvement in depression prior to initiation of
HAART (slope= -0.1229, p=0.0321), but neither the slope following HAART initiation
(slope=0.1005, p=0.2308) nor the aggregate trajectory of POMS over total follow-up was
significant (slope=-0.2246, p=0.7136). This data is represented by the spaghetti plots in
Figures 10 (BDI) and 11 (POMS). On top of the lines, which connect each subject’s
trajectory, we have superimposed a Loess curve for each dataset to summarize the
smooth average values of the data at each interval for visualization purposes. However,
the statistical model that we used is more sophisticated than the Loess and factors in the
variable duration and intervals of follow up for each subject, as well as their pre- versus
post- HAART initiation status.
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Figure 10. Longitudinal Total BDI Scores. Longitudinal BDI Total scores in those 60,
of the initial 65 subjects with longitudinal follow-up, both before and after HAART
initiation. Individual subject’s scores are represented here as symbols connected by lines
to demonstrate the BDI score trajectory. A Lowess curve is superimposed on the lines to
show the average scores at each time point and to provide an overview of the trajectory,
but the more complex mixed model weights number of visits per subject and duration of
follow-up. In this study, subjects had a total of 330 total visits, 196 of these off of ART.
There were no changes in the BDI scores over a median 54 weeks of follow-up in
longitudinal mixed model analyses either prior to or following HAART initiation (slope
of change prior to treatment over time -0.02038 change per week, p=0.1238; slope of
change following ART= -0.0020, p=0.9107). The aggregate overall BDI trajectory
(including pre- and post- HAART visits) also did not significantly change over the course
of follow-up (slope= -.02239, p=0.0748).
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Figure 11. Longitudinal POMS Total Mood Disturbance Scores. Longitudinal POMS
Total Mood Disturbance scores in those 60, of the initial 65 subjects with longitudinal
follow-up, both before and after HAART initiation. Individual subject’s scores are
represented here as symbols connected by lines to demonstrate the BDI score trajectory.
A Lowess curve is superimposed on the lines to show the average scores at each time
point and to provide an overview of the trajectory, but the more complex mixed model
weights number of visits per subject and duration of follow-up.
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In this study, subjects had a total of 330 total visits, 196 of these off of ART.
Except for a modest improvement in POMS prior to starting HAART (slope= -0.1229,
p=0.0321), there was no significant change in POMS scores over a median 54 weeks of
follow-up in longitudinal mixed model analyses; neither the slope following HAART
initiation (slope=0.1005, p=0.2308) nor the aggregate trajectory of POMS over total
follow-up was significant (slope=-0.2246, p=0.7136).
Finally, to assess potential effects of timing of HAART initiation in the outcome
of mood in early HIV infection, we examined whether post-ART POMS and BDI scores
correlated with number of weeks from initial infection that HAART was started. In
neither all subjects who started ART, nor the 18 subjects with at least 6 months sustained
treatment with ART, were any significant associations detected between timing of the
start of therapy (expressed as weeks from infection, a continuous factor) and subsequent
BDI or POMS levels (data not shown).

DISCUSSION
We report on depression and mood states in 65 study participants who we followed
longitudinally beginning in PHI. At baseline, we explored their depression and mood
states as measured by the POMS and BDI and examined whether these correlated with
neurological measures of inflammation and blood-brain barrier breakdown or
performance on neuropsychological testing. Over a median 54 weeks follow-up, we also
examined a model for depression and mood states pre- and post-initiation of ART.
Depression is a Significant Problem in PHI
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Studies have reported varying prevalence of depression over the course of HIV infection
(37-39,41), though only one other study examined the population during PHI (68). Using
the POMS and BDI, measures of mood that are considered valid and internally consistent
(83,84) and have been used to measure depression with good validity and reliability in
HIV infected patients (42,53,85), we determined that 47.7% of HIV-infected subjects at
an estimated three and half months after HIV transmission experience clinical depression.
While the overall prevalence of depression in our population was slightly higher (47.7 %
as compared to 40 %), our findings resembled the results of the only other study, by
Atkinson and colleagues (68), in that the vast majority of our PHI subjects experienced a
minimal or mild depression (11 out of 65 subjects and 34 out of 65 subjects,
respectively), as compared to a severe depression (9 out of 65). One subject in our study,
however, did commit suicide, underscoring the potential severity of symptoms of
depression that HIV-infected persons may experience. From this data, it is evident that
depression is a significant and prevalent problem during PHI.
As other chronic illnesses have been known to have 2-3 fold higher depression
rates than the general population (35), our nearly 48% rate of depression during PHI
supports the hypothesis that with HAART, HIV has features which parallel other chronic
illnesses in the US population (7). Given that depressed patients who are chronically ill
more frequently report physical symptoms and more pain (35,36), it is perhaps not
surprising that in our study, as in other studies (42), HIV infected subjects experienced
more somatic symptoms than cognitive/affective symptoms of depression. This was
reflected in the increased BDI somatic-performance subscale as compared to the
cognitive/affective subscale. These somatic symptoms could be associated with HIV
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infection and its manifestations (38), and could be considered a confounding variable in
the measurement of depression in this group. Additionally, the vigor subscale score was
significantly lower than the other measured mood states, which may be expected in those
experiencing a physical illness. However, given that as depression increases as physical
symptoms of HIV infection increase (44), measuring depression in this population with
reliable self-report tests might ideally be supplemented by psychological interviews.
What Causes Depression in HIV Infection?
Similar to the previous literature, our study is unable to definitively conclude what
actually causes depression in HIV infected persons. One hypothesis suggests that
depression is a premorbid condition in a person at high risk of HIV acquisition, or, in
other words, a depressed person is inherently at a high risk to contract HIV (58). To
support this theory, we would expect depression to be elevated in this population due to
other confounding risk factors often associated with mood disorders, such as sexuality or
substance use (58). However, as measured by either BDI or POMS in our study,
depression was not associated with substance use, despite a high prevalence of alcohol
and drug use in our cohort. In addition, though depression has been found to correlate
with gender, social class, suicide attempts, and MSM in past studies (37, 38), we had a
homogenous group of 100% male subjects with all but 3 self-identifying as MSM,
controlling for some of these variables.
Another hypothesis postulates that depression in HIV is reactionary, and also
associated with the manifestations and treatment of HIV itself. The high prevalence of
clinical depression during PHI, a period characterized by dramatic systemic physiological
effects, the emotional stress of recent disease diagnosis, and in some cases complex or
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chaotic social settings, which led to infection, supports this theory. Additionally, as
stigma in this population has been shown to correlate significantly with higher levels of
depression (45,48,49), high levels of depression following diagnosis is not unexpected.
However, given these social, emotional, and physical changes, one might expect the level
of “severe” depression during this baseline period to be much higher than we detected
(‘severe’ n=9). Also, both the opportunistic infections associated with HIV, and the side
effects of antiretroviral therapy, are known to cause depression (38). In fact, one study
found that increased side effects from treatment actually predicted depression (45). By
selecting a population of treatment naive individuals, we protected against side effects
causing any physical manifestations of depression. However, looking longitudinally after
initiation of HAART, it becomes more difficult to assess whether symptoms such as
insomnia that might manifest as high somatic performance scores and therefore higher
scores on the total BDI, are a result of clinical depression or HAART.
The final hypothesis for the development of depression during HIV suggests that
there is a biological basis for disease. It is believed that cytokines, stress and cortisol, and
the inhibition of dopamine, could all cause depression in the HIV infected person (38 34,
48, 81). However, in our study, the lack of correlations between the BDI and POMS and
any laboratory indices of disease (including blood or CSF HIV viral load or blood CD4
count), suggests that depression should be considered independently from neuropathic
HIV infection. This might also suggest that the high levels of depression in our
population are reactive, and despite elevated somatic performance scores on the BDI, not
caused by HIV infection’s influence on the physical and biological. Furthermore, our
findings support the previous studies in chronic HIV indicating no association between
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CD4 count, viral load, and depression, though there has been some conflicting evidence
suggesting an association between these parameters and mood in HIV infected subjects at
later stages of illness (38, 51). It is possible that unmeasured physiological effects
contribute to mood disorders during the early stages of HIV infection, or, more likely,
that the variable extent of HIV viral burden and host immune responses to early infection
are independent of an individual’s self-reported mood.
The lack of correlation between mood and neuropsychological testing further
suggests that HIV is independent from depression, and conversely that impaired
neurocognitive performance in this period is not directly caused by mood disturbance.
While one might expect mood to influence cognitive performance as PHI alone is known
to cause neuropsychological impairment (67), in our study, similar to the data found in
additional studies that measured depression alone, or depression in those with HIV
(86,87), neuropsychological performance (summarized as total Z and GDS) did not
associate with BDI or POMS Total Mood Disturbance. The lack of correlation between
performance and mood is important to interpretations of cognitive status during this early
period of infection as poor performance in some subjects (67) might be attributed to
disturbed mood during this challenging period. Our findings also suggests that the
mechanisms of depression and other CNS pathology in HIV are different, as cognitive
performance is impaired during PHI, but performance does not correlate with measures
of depression during PHI. Therefore, early depressive symptoms are unlikely to be a
predictor for early HIV-associated neurocognitive disorder (HAND), and may also be
unrelated to its’ later development. Though this study confirms that depression
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prevalence is high in PHI, it remains uncertain whether depression is a predisposing
factor to developing HIV or is, instead, an early result of the HIV infection itself.
What Happens to Depression Over Time?
Studies have suggested that depression can impact HIV disease progression and mortality
(59). This is not shocking as depressed patients, even without a chronic illness, have been
known to die 5 to 10 years earlier than patients without mood disorders (35). Yet, similar
to effects of depression on treatment adherence in other chronic illnesses, non-adherence
is high in patients with HIV and depression (60). Given that HAART has been postulated
to have lowered the infection rates significantly (2) and to have increased life expectancy
to close to the levels of the uninfected population with chronic disease (5), it is not
surprising that HAART non-adherence is thought to contribute to the increased mortality
found in depressed patients with HIV. One study even went so far as to postulate a
protective effect of HAART, finding a decrease in depression with increased time on
HAART (61).
Our longitudinal data, however, does not support this theory. We found that the
overall group’s BDI and POMS scores did not significantly change prior to or following
initiation of HAART. This lack of statistically significant improvement in our results
following treatment suggests that the course of HIV infection itself and its subsequent
treatment with HAART might not play a role in alleviation of depression in PHI.
Depression is also not changed whether the subject began HAART immediately after
diagnosis, or later in the course of the disease.
Overall, depression appears at a low level throughout the course of early HIV in
our subjects suggesting that depression is persistent, regardless of causation, following
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infection. Our results also suggest that “watchful waiting” did not improve depression
scores except for a minor improvement in the POMS (slope=-.1229, p=0.0321) prior to
ART, which was not sustained over the course of the pre- and post- HAART follow-up.
One might expect time to improve depression, given the expectation that after adjustment
to the news of HIV diagnosis there may be a natural improvement in mood over time
without intervention. Since we did not see an improvement with the natural history of
early HIV, it is possible that depression in this population also is less likely to be reactive,
and more likely to be either a pre-morbid or HIV-related condition.
Since depression is associated with lower adherence to HAART (62) and new
treatment guidelines for HIV suggest commencing HAART at initial diagnosis (24),
recognizing and treating depression in this population is important in management of
HIV. Since it remains possible that depression in PHI is related to HIV infection itself,
given the high somatic scores on the BDI, a synergistic approach to HAART and
antidepressants might be an effective strategy in patients, especially those with early
infection. Ultimately, the effects of treatment for depression, HAART adherence, HIV
disease and symptom presentation in the early stages after HIV infection and diagnosis
are in need of closer examination.
Limitations
The limitations of this study include a homogeneous population, primarily men who have
sex with men (MSM) who live in the San Francisco area. In addition, depression is
measured by self-report; however the scales correlate with each other suggesting internal
consistency between our results. HAART adherence is also self-reported, though
observation of persistent virological suppression this group (data not shown) suggests
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excellent adherence over time in the subjects. The longitudinal correlations might be
skewed by the effects of antidepressant usage, which are not included in our analysis, and
the lack of randomization into ART. Also, we did not take an in depth psychological
history at study visits, and merely relied on self-report of previous treatment for
depression or bipolar disorder. This made it difficult to truly control for all of the
psychological confounding variables that could affect depression rates in this population
(e.g., previous suicidal attempts, antidepressant usage, previous treatment).
Implications of Research for the HIV Field
Our finding of 47.7% clinical depression in PHI has important implications for the
management of patients with HIV. Since depression is associated with lower adherence
to HAART (62) and new treatment guidelines for HIV suggest commencing HAART at
initial diagnosis of HIV (24), our results would suggest that at diagnosis, it is also
important to recognize and treat depression. Though the depression is more often mild or
moderate, it can be severe, leading to suicide in these patients. Thus, beyond preventing
non-adherence and resistance to HAART, treating depression might also save a life from
self-harm.
As depression does not seem to correlate with CSF measures of inflammation or
disease or with neuropsychological testing, self-assessment and psychiatric consultation
will be the most effective means of screening during PHI. In order to properly diagnose
these patients, physicians must understand that the physical manifestations of disease
may resemble depression (38), and must learn to screen by asking more about mood,
anhedonia, and decreased energy than sleep and appetite changes (38). They must also
recognize that depression may have been pre-morbid, and might seek to provide support,
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suggest therapy or social services, or even drug rehabilitation, for their patients to help
with the additional life factors that may be contributing to their depression.
It also remains possible that depression in PHI is related to HIV infection itself,
given the high somatic scores on the BDI. The literature has suggested that
antidepressants are effective in this population (38,41,58,62), and in fact, substantially
increase adherence to HAART (63). Therefore, a synergistic approach to HAART and
antidepressants might be an effective strategy in patients, especially those with early
infection. Also as our study suggests that depression remains consistent over time, despite
initiation of ART, pharmacological treatment of depression may be the only way to
significantly improve depression, with a significant impact of decreasing plasma viral
load (65) in this population. Ultimately, the effects of treatment for depression, HAART
adherence, HIV disease and symptom presentation in the early stages after HIV infection
and diagnosis are in need of closer examination.
Future Directions
While we have characterized depression during PHI in our particular population, as it was
only the second study of this early infection time period, it would be extremely useful to
look at other populations for comparison. Given that this population was composed of
only males, and studies have suggested higher rates of depression in females and
increased mortality in females with HIV infection (43,55), doing a comparison study with
women would be very important. Additionally, having a comparison group of matched
individuals without HIV infection, or with another chronic illness, might help to better
understand depression in this population as it relates to other chronic diseases and the
“healthy” population.
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Furthermore, though we were able to measure depression longitudinally in our
population as an exploratory study, a more controlled environment would help to better
describe the trajectory of depression. It would be necessary to document not only
HAART initiation, but also treatment for depression, to see if antidepressant
commencement or therapy initiation altered the prevalence of depression over time in any
way.
Finally, as we continue to study with whether depression was concomitant or was
a result of the disease itself, we need to take a better assessment of stigma and support,
psychological factors (like previous psychiatric treatment, suicide, or diagnoses), and
substance use at baseline and over time. As depression is often a product of the social as
well as the biological, these factors might contribute significantly to the high rates of
depression we are seeing in this population.
Conclusions
While HIV may no longer be a death sentence upon diagnosis, depression may shorten an
HIV-infected person’s life, whether by nonadherence to HAART or self-harm. This
depression is highly prevalent, and though it is usually mild, it may be severe; in fact one
of our 65 study subjects committed suicide during this early period. While it remains
unclear whether depression is a predisposing factor to HIV infection or it is an early
result of HIV infection itself, or whether it is merely persistent regardless of cause, this is
an important area for future research and disease management protocols. Since HAART
adherence is affected so significantly by depression, and failure to adhere leads to disease
mutations and resistance to drugs as well as disease progression, screening for and
properly treating depression in this population is critical. Targeted interventions for
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depression in the early stages of infection may have an impact not only on psychological
but also systemic outcomes in HIV.
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